Biogen (BIIB) Could Be 9% Undervalued As Pipeline Hopes Shape The Valuation

Simply Wall St.06-25

AdvertisementBiogen Stock Performance Snapshot Biogen (BIIB) has drawn investor attention after a period of mixed long term returns, with the stock showing a 0.6% move over the past week and a month ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2646189820?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-06-25 15:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2646189820","market":"nz","top_or_hot":-1,"title":"Biogen (BIIB) Could Be 9% Undervalued As Pipeline Hopes Shape The Valuation","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementBiogen Stock Performance Snapshot Biogen (BIIB) has drawn investor attention after a period of mixed long term returns, with the stock showing a 0.6% move over the past week and a month ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-biib/biogen/news/biogen-biib-could-be-9-undervalued-as-pipeline-hopes-shape-t\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen (BIIB) Could Be 9% Undervalued As Pipeline Hopes Shape The Valuation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen (BIIB) Could Be 9% Undervalued As Pipeline Hopes Shape The Valuation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-25 15:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-biib/biogen/news/biogen-biib-could-be-9-undervalued-as-pipeline-hopes-shape-t><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementBiogen Stock Performance Snapshot Biogen (BIIB) has drawn investor attention after a period of mixed long term returns, with the stock showing a 0.6% move over the past week and a month ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-biib/biogen/news/biogen-biib-could-be-9-undervalued-as-pipeline-hopes-shape-t\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-biib/biogen/news/biogen-biib-could-be-9-undervalued-as-pipeline-hopes-shape-t","article_id":"2646189820","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-biib/biogen/news/biogen-biib-could-be-9-undervalued-as-pipeline-hopes-shape-t","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2646189820","pubTimestamp":1782371986,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Biogen Stock Performance Snapshot\nBiogen (BIIB) has drawn investor attention after a period of mixed long term returns, with the stock showing a 0.6% move over the past week and a month return of 3.0% heading into late June 2026.\nSee our latest analysis for Biogen.\nLooking beyond the recent moves, Biogen’s 12.2% year to date share price return, alongside a 56.8% total shareholder return over the past year but weaker multi year total returns, suggests momentum has picked up recently after a...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","BIIB":"渤健公司","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","BK4588":"碎股","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4585":"ETF&股票定投概念","BK4532":"文艺复兴科技持仓","BK4533":"AQR资本管理(全球第二大对冲基金)"},"translate_title":"由于管道希望影响估值，Biogen(BIIB)的估值可能被低估9%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":1.5},"content_text":"AdvertisementBiogen Stock Performance Snapshot Biogen (BIIB) has drawn investor attention after a period of mixed long term returns, with the stock showing a 0.6% move over the past week and a month return of 3.0% heading into late June 2026. See our latest analysis for Biogen. Looking beyond the recent moves, Biogen’s 12.2% year to date share price return, alongside a 56.8% total shareholder return over the past year but weaker multi year total returns, suggests momentum has picked up recently after a tougher stretch for long term holders. If you are comparing Biogen with other potential opportunities in healthcare, this could be a good moment to see what is happening across specialist biotech and 38 healthcare AI stocks With Biogen trading at $199.59, carrying a value score of 4 and a modelled intrinsic discount of 52.8%, investors are left asking whether this is a genuine mispricing or if the market is already factoring in future growth. Most Popular Narrative: 9% Undervalued Based on the most widely followed narrative, Biogen’s fair value of $219.27 sits above the current $199.59 share price, which frames the stock as undervalued in that model.  Robust late stage and diversified neurodegenerative and specialty disease pipelines including Phase III launches in SMA, lupus, and kidney indications capitalize on regulatory momentum to address high unmet needs, creating multiple shots on goal that reduce future revenue volatility and support long term earnings stability.  Read the complete narrative. Curious what kind of revenue profile, margin uplift, and future earnings power this narrative is baking in, and how those inputs tie back to that higher fair value estimate. Result: Fair Value of $219.27 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, Biogen’s story also carries execution risks, including pressure on its multiple sclerosis franchise and uncertainty around newer launches like LEQEMBI and ZURZUVAE as they work to gain traction. Find out about the key risks to this Biogen narrative. Another View on Biogen’s Valuation The first narrative frames Biogen as undervalued using analyst fair value estimates, but the earnings multiple tells a more mixed story. Biogen trades on a P/E of 21.5x, above the US Biotechs industry at 16.7x, yet below peers at 26.9x and close to a fair ratio of 23.1x. This raises the question of whether that points to limited upside or room for the market to close the gap. See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:BIIB P/E Ratio as at Jun 2026Next Steps With mixed signals across Biogen’s momentum and valuation, are you leaning bullish or cautious, and how quickly do you want to firm up that view? To balance the 1 or more risks investors are watching against the 1 or more rewards they are optimistic about, review the 2 key rewards and 1 important warning sign Looking for more investment ideas beyond Biogen? If Biogen has sharpened your focus on opportunities in healthcare, do not stop here. Broaden your watchlist with a few targeted sets of stocks right now.  Target potential mispricings by scanning a curated group of companies that appear attractively valued using the 44 high quality undervalued stocks. Prioritize resilience by reviewing businesses that currently feature in the 69 resilient stocks with low risk scores. Hunt for future standouts before they hit the spotlight by checking the screener containing 18 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Biogen might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2646189820","isCrawlerRequest":true}